The estimated Net Worth of Langdon L Miller is at least $105 mil dollars as of 22 July 2021. Langdon Miller owns over 10,000 units of Cytocom Inc stock worth over $31,700 and over the last 10 years he sold CBLI stock worth over $0. In addition, he makes $73,725 as President e Chief Medical Officer at Cytocom Inc.
Langdon has made over 1 trades of the Cytocom Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of CBLI stock worth $30,000 on 22 July 2021.
The largest trade he's ever made was exercising 10,000 units of Cytocom Inc stock on 22 July 2021 worth over $30,000. On average, Langdon trades about 5,000 units every 0 days since 2015. As of 22 July 2021 he still owns at least 10,000 units of Cytocom Inc stock.
You can see the complete history of Langdon Miller stock trades at the bottom of the page.
Dr. Langdon L. Miller M.D. serves as President, Chief Medical Officer of the Company. He previously served as a strategic adviser to the Company beginning in 2014. Dr. Miller has maintained a drug development consultancy, Sound Clinical Solutions, SP, located in Seattle, WA since 2013 and has served as a consulting Chief Medical Officer to Oncternal Therapeutics, Inc., located in San Diego, CA, since August 2016. Dr. Miller has served on the board of Dunn Gardens, a private, not-for-profit organization, since 2013 and was appointed to the board of Swedish Club, a private, not-for-profit organization in April of 2019. Since April 2018, Dr. Miller has also served as Executive Vice President and Chief Medical Officer of VelosBio Inc., a private biopharmaceutical company. Dr. Miller has more than 25 years of experience in the design and conduct of translational and clinical drug development programs in oncology (both in hematological and solid tumors) and orphan diseases (including cystic fibrosis, muscular dystrophy, and hemophilia). He has worked in all phases (phase 1-4) of drug development, from first-in-human studies through pivotal registration-directed trials to medical affairs programs and has filed multiple INDs, CTAs, NDAs and orphan drug applications. Dr. Miller played major roles in the development of filgrastim and sargramostim, in the regulatory approvals of irinotecan, exemestane, epirubicin, dexrazoxane, sunitinib, and idelalisib in several cancers, and in validating new endpoints for Duchenne muscular dystrophy and cystic fibrosis. He has extensive experience in the generation, analysis, presentation, and justification of drug development programs before regulatory authorities, advisory committees, investigators, investors, and business development partners. He has authored over 100 regulatory documents and publications. Dr. Miller has held leadership positions in government and in large and small biopharmaceutical companies. He was a Senior Investigator at the National Cancer Institute from 1989 to
As the President e Chief Medical Officer of Cytocom Inc, the total compensation of Langdon Miller at Cytocom Inc is $73,725. There are 1 executives at Cytocom Inc getting paid more, with Christopher Zosh having the highest compensation of $103,494.
Langdon Miller is 66, he's been the President e Chief Medical Officer of Cytocom Inc since 2015. There are no older and 8 younger executives at Cytocom Inc.
Langdon's mailing address filed with the SEC is C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO, NY, 14203.
Over the last 17 years, insiders at Cytocom Inc have traded over $1,157,190 worth of Cytocom Inc stock and bought 66,403 units worth $199,902 . The most active insiders traders include James Antal, Michael Fonstein, eBernard L Kasten. On average, Cytocom Inc executives and independent directors trade stock every 101 days with the average trade being worth of $21,921. The most recent stock trade was executed by Langdon L Miller on 22 July 2021, trading 10,000 units of CBLI stock currently worth $30,000.
Cytocom Inc executives and other stock owners filed with the SEC include: